ADA Home Page
Catalog | Find a Dentist | Seal Program | Contact  
 
Dental Professionals Your Oral Health The ADA
Animations and Games
Careers
Students and Educators
Espanol
Events
Manage Your Oral Health
Media Press Room
MEDIA VIDEOS
NEWS RELEASES
PRESS KITS
Topics and Resources

News Releases
  Current Releases   Sign Up: Media E-mail List Link opens in separate window. Pop-up Blocker may need to be disabled.
  Archive  

Contact Information:
Telephone: 312-440-2806
E-mail: mediarelations@ada.org (Journalists) or Contact ADA (All Others)

Oral Bisphosphonate Risk Slight, But Dental Patients Should Be Aware, ADA Says

CHICAGO, August 4, 2006—People taking oral bisphosphonates, a type of drug used to treat osteoporosis, osteopenia and Paget’s disease of bone, should be aware of potential risks when undergoing certain dental procedures, according to guidelines published in this month’s Journal of the American Dental Association (JADA).

Relying on a small but growing number of reports linking bisphosphonate drugs to incidences of osteonecrosis of the jaw (dead bone tissue), a panel of experts convened by the ADA believes dental patients who are taking oral bisphosphonate drugs should discuss the risks they face when undergoing procedures that involve the jaw bone, such as tooth extraction or placing implants, with their dentist. Dentists and their patients should carefully consider these procedures, as well as alternative dental therapies. Patients may also want to discuss this information in the context of their overall health and treatment options with their physician.

The ADA recommends that a comprehensive oral evaluation be carried out on all patients about to begin therapy with oral bisphosphonates (or as soon as possible after beginning therapy), and that patients on these drugs be educated on maintaining oral hygiene, which is the best way to prevent oral diseases that may require dental surgery.

The ADA notes that dentists, generally, will not need to modify dental treatments based solely on oral bisphosphonate therapy. Further, patients should understand that the risk for developing osteonecrosis of the jaw is considered very small and that the vast majority of patients taking an oral bisphosphonate do not develop any oral complication.

More information is available at www.ada.org/public/topics/osteonecrosis.asp

About the American Dental Association

Celebrating its 150th anniversary, the not-for-profit ADA is the nation's largest dental association, representing more than 156,000 dentist members. The premier source of oral health information, the ADA has advocated for the public's health and promoted the art and science of dentistry since 1859. The ADA's state-of-the-art research facilities develop and test dental products and materials that have advanced the practice of dentistry and made the patient experience more positive. The ADA Seal of Acceptance long has been a valuable and respected guide to consumer dental care products. The monthly Journal of the American Dental Association (JADA) is the best-read scientific journal in dentistry. For more information about the ADA, visit the Association's Web site at www.ada.org

Return to Top

Quick Links
ADA Positions & Statements
Oral Health Topics
Video News Release: Oral Cancer
Copyright 1995-2008 American Dental Association.
Reproduction or republication strictly prohibited without prior written permission.
See Privacy Policy (Updated 03/14/05) and Terms of Use for further legal information.
Link opens in separate window. Pop-up Blocker may need to be disabled. Link opens in separate window.
Pop-up Blocker may need to be disabled.
Member Only Content Member only content.